AGC biologics acquisition cell and gene therapy

[NEWS] AGC Biologics has Completed Acquisition of Novartis’ Colorado Cell and Gene Therapy Manufacturing Facility

Update 11th August 2021 - AGC Biologics has confirmed completion of the acquisition of a state-of-the-art commerical manufacturing facility in Colorado, previously owned by Novartis Gene Therapies. 
Patricio Massera, CEO of AGC Biologics, commented: 

“The Longmont facility is just one of the company-wide expansion initiatives that AGC Biologics has been working on. With our ongoing global expansion, we look forward to continuing to help our partners bring life-saving treatments to the market.”

For more information about the acquisition, read the orginial story below. 

Source: AGC Biologics press release 

AGC Biologics to Acquire Novartis’ Colorado Cell and Gene Therapy Manufacturing Facility

Originally published 7th July 2021 -  The acquisition – pending final due diligence – is expected to significantly expand AGC Biologics’ cell and gene therapy capabilities.

AGC Biologics has announced a signed purchase agreement for the acquisition of a cell and gene therapy commercial manufacturing facility from Novartis Gene Therapies.

The CDMO claims that the new facility will provide ‘significant’ additional capacity and space for expanding its current cell and gene therapy offering, thus providing security of supply for customers.

Patricio Massera, AGC Biologics CEO, explained:

“The Longmont facility fits perfectly into AGC’s long-term growth and expansion plans. This move is driven by our dedication to satisfy the needs of our current and future customers.”

You might also be interested in:
Situated in Longmont, Colorado, the new facility is only 16 miles from AGC Biologics’ mammalian facility in Boulder, and just 40 minutes north of Denver. Adding 622,000 square feet of operations and office space within six buildings over 229 acres, AGC has also reported that a significant percentage of talented staff currently under the employ of Novartis will be hired under AGC Biologics stewardship.

Since the award-winning acquisition of MolMed in 2020, AGC has continued to invest heavily in cell and gene therapy, becoming one of the very few CDMOs offering end-to-end cell and gene therapy services, including plasmid production of all grades.

News of the site acquisition comes shortly after other announcements from AGC Biologics including an expansion at its Centre of Excellence for Cell and Gene Therapy in Milan, a partnership expansion with Rocket Pharmaceuticals for the advancement of gene therapies for rare childhood disorders, and the doubling of production capacity at a Denmark site to address strong demand.  

AGC Biologics CBO, Mark Womack, concluded:

“Adding this facility into our global network will be one more step towards our vision of being able to offer our partners, whatever they need it, wherever they need it.”

Source: AGC Biologics press release